SEC Contract Filing

Filing Date: 2017-08-28

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>life-ex101_238.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
life-ex101_238.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES PURCHASE AGREEMENT</p>
<p style="margin-top:12pt;margin-bottom:12pt;text-align:justify;text-indent:7.46%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Securities Purchase Agreement (this &#8220;<font style="font-style:italic;">Agreement</font>&#8221;) is dated as of August&#160;27, 2017 by and among aTyr Pharma, Inc., a Delaware corporation (the &#8220;<font style="font-style:italic;">Company</font>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<font style="font-style:italic;">Purchaser</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;">Purchasers</font>&#8221;). </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:14.93%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;">The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;</font><font style="font-style:italic;">Securities Act</font>&#8221;), and Rule 506 of Regulation D (&#8220;<font style="font-style:italic;">Regulation D</font>&#8221;) as promulgated by the United States Securities and Exchange Commission (the &#8220;<font style="font-style:italic;">Commission</font>&#8221;) under the Securities Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:14.93%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:14.93%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;">Each Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i)(a) that aggregate number of shares of common stock, par value $0.001 per share (the &#8220;</font><font style="font-style:italic;">Common Stock</font>&#8221;), of the Company, set forth below such Purchaser&#8217;s name on the signature page of this Agreement (which aggregate amount for all Purchasers together shall be 5,872,120 shares of Common Stock and shall be collectively referred to herein as the &#8220;<font style="font-style:italic;">Common Shares</font>&#8221;) and (b) warrants (the &#8220;<font style="font-style:italic;">Warrants Relating to Common Shares</font>&#8221;), in substantially the form attached hereto as <font style="text-decoration:underline;">Exhibit A</font>, to acquire up to that number of additional shares of Common Stock equal to thirty seven and one half percent (37.5%) of the number of Common Shares purchased by such Purchaser (rounded up to the nearest whole share); and (ii)(a) that aggregate number of shares of Class X Preferred Stock, par value $0.001 per share (the &#8220;<font style="font-style:italic;">Preferred Stock</font>&#8221;), of the Company, set forth below such Purchaser&#8217;s name on the signature page of this Agreement (which aggregate amount for all Purchasers together shall be 2,285,952 shares of Preferred Stock and shall be collectively referred to herein as the &#8220;<font style="font-style:italic;">Preferred Shares</font>&#8221; and together with the Common Shares, the &#8220;<font style="font-style:italic;">Shares</font>&#8221;) and (b)&#160;warrants (the &#8220;<font style="font-style:italic;">Warrants Relating to Preferred Shares</font>&#8221; and together with the Warrants Relating to Common Shares, the &#8220;<font style="font-style:italic;">Warrants</font>&#8221;), in substantially the form attached hereto as <font style="text-decoration:underline;">Exhibit A</font>, to acquire up to that number of additional shares of Common Stock equal to one hundred eighty seven and one half percent (187.5%) of the number of Preferred Shares purchased by such Purchaser (rounded up to the nearest whole share).&nbsp;&nbsp;The shares of Common Stock issuable upon exercise of or otherwise pursuant to the Warrants are referred to herein as &#8220;<font style="font-style:italic;">Warrant Shares</font>&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.46%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:14.93%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;">The Shares, the Warrants, the Warrant Shares and the Underlying Shares (as defined below) collectively are referred to herein as the &#8220;</font><font style="font-style:italic;">Securities</font>&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:14.93%;font-siz